Data as of Q4 2025 (Dec 31, 2025)

bioAffinity Technologies, Inc.

(BIAF)

Financial Statements · SEC EDGAR XBRL

Revenue
$6.2M
-34.2%
Net Income
-$14.9M
-64.9%
EPS
$-8.66
+61.5%
Op. Income
-$10.6M
-18.1%
FCF
-$9.4M
-27.9%
Source: SEC EDGAR XBRL
Breakdown
Revenues
Revenues
Total Revenues
Cost of Revenues
Gross Profit
Operating Expenses & Income
Selling General & Admin
Research & Development
Total Operating Expenses
Operating Income
Non-Operating Income/Expense
Interest Income/Expense
Other Non-Operating Income
Pre-Tax Income
Income Tax Expense
Net Income
EPS (Basic)
EPS (Diluted)
Shares Outstanding (Diluted)
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
$6.2M
$9.4M
$2.5M
$5K
-
$6.2M
$9.4M
$2.5M
$5K
-
-
-
-
$467
-
-
-
-
$4K
-
$9.9M
$9.9M
$6.8M
$2.5M
$1.1M
$1.4M
$1.5M
$1.5M
$1.4M
$1.0M
$16.7M
$18.3M
$10.5M
$4.0M
$2.2M
-$10.6M
-$9.0M
-$8.0M
-$4.0M
-$2.2M
-
-
$37K
$2.5M
$1.0M
-$4.3M
-$75K
$57K
-$4.1M
-
-$14.9M
-$9.0M
-$7.9M
-$8.2M
-$6.3M
$44K
$12K
$21K
$2K
$2K
-$14.9M
-$9.0M
-$7.9M
-$8.2M
-$6.3M
$-8.66
$-22.50
$-0.91
$-1.81
$-2.36
$-8.66
$-22.50
$-0.91
$-1.81
-
1.7M
404K
8.7M
4.5M
-